Mehran R, Baber U, Sharma SK, et al. – Via conducting a double-blind trial, experts investigated the impact of ticagrelor alone vs ticagrelor plus aspirin on clinically significant bleeding in individuals at high risk for bleeding or an ischemic event who had undergone percutaneous coronary intervention (PCI). Of the 9,006 people recruited, 7,119 were randomized after 3 months. Compared with those who received ticagrelor plus aspirin, participants who received ticagrelor monotherapy demonstrated a lower incidence of clinically relevant bleeding, with no higher risk of death, myocardial infarction, or stroke.